Jounce Therapeutics, Inc. (NASDAQ:JNCE) CFO Kimberlee C. Drapkin sold 2,697 shares of the business’s stock in a transaction dated Thursday, January 7th. The stock was sold at an average price of $6.76, for a total value of $18,231.72. Following the sale, the chief financial officer now directly owns 59,011 shares of the company’s stock, valued at $398,914.36. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Shares of JNCE stock opened at $7.33 on Thursday. The stock has a market cap of $292.11 million, a PE ratio of -2.44 and a beta of 1.36. The stock has a 50-day moving average of $6.88 and a 200-day moving average of $6.99. Jounce Therapeutics, Inc. has a one year low of $2.85 and a one year high of $11.72.
Jounce Therapeutics (NASDAQ:JNCE) last issued its quarterly earnings data on Friday, November 6th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.36). Analysts anticipate that Jounce Therapeutics, Inc. will post -2.21 EPS for the current year.
Several analysts have weighed in on the company. BidaskClub raised Jounce Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, January 1st. Raymond James cut Jounce Therapeutics from a “strong-buy” rating to a “market perform” rating in a report on Monday, November 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of Jounce Therapeutics in a research note on Friday, December 4th. Roth Capital lowered their price target on Jounce Therapeutics from $28.00 to $15.00 and set a “buy” rating for the company in a research note on Tuesday, November 10th. Finally, ValuEngine raised Jounce Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, December 1st. One research analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company. Jounce Therapeutics presently has an average rating of “Hold” and a consensus price target of $11.38.
About Jounce Therapeutics
Jounce Therapeutics, Inc, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase II clinical trial for the treatment of PD-1/PD-L1 inhibitor patients with non-small cell lung cancer and urothelial cancer.
Further Reading: Why is the price target of stocks important?
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.